CA2446738A1 - Abuse-resistant opioid dosage form - Google Patents

Abuse-resistant opioid dosage form Download PDF

Info

Publication number
CA2446738A1
CA2446738A1 CA002446738A CA2446738A CA2446738A1 CA 2446738 A1 CA2446738 A1 CA 2446738A1 CA 002446738 A CA002446738 A CA 002446738A CA 2446738 A CA2446738 A CA 2446738A CA 2446738 A1 CA2446738 A1 CA 2446738A1
Authority
CA
Canada
Prior art keywords
dosage form
pharmaceutical dosage
oral pharmaceutical
abuse resistant
resistant oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002446738A
Other languages
French (fr)
Other versions
CA2446738C (en
Inventor
Huai-Hung Kao
Yadi Zeng
Michelle Howard-Sparks
Fai Jim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2778114A priority Critical patent/CA2778114A1/en
Publication of CA2446738A1 publication Critical patent/CA2446738A1/en
Application granted granted Critical
Publication of CA2446738C publication Critical patent/CA2446738C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

The present invention pertains to a pharmaceutical dosage from comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist. The separate matrix for the opioid antagonist allows independent release rates to be achieved for the opioid and opioid antagonist(s). The antagonist(s) can be released slowly or fully contained when the tablet is taken orally. Crushing the tablet allows full release of the antagonist(s), deterring abuse. The abuse deterring antagonist(s) may be an opioid antagonist, an irritant, another appropriate antagonist(s), or a combination thereof. The invention also allows variable release of the opioid and antagonist(s).

Claims (57)

1. An abuse resistant oral pharmaceutical dosage form comprising:
a first matrix including a first opioid antagonist;
a second matrix including an opioid agonist; and a coating including a second opioid antagonist;
wherein said tablet, when intact, is adapted to release at least about 30% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV
Apparatus I, basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
2. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein when said tablet is adapted to release, when crushed, at least about 75% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
3. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said second opioid antagonist is different from said first opioid antagonist.
4. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said first and second opioid antagonists are the same.
5. The abuse resistant oral pharmaceutical dosage form of Claim 3 wherein said first opioid antagonist is naltrexone and said second opioid antagonist is naloxone.
6. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said tablet is adapted to release at least about 50% of the total antagonist in the first hour.
7. The abuse resistant oral pharmaceutical dosage form of claim 1 wherein said first matrix is dispersed in said second matrix.
8. The abuse resistant oral pharmaceutical dosage form of claim 7, wherein said first matrix is coated to prevent release of said first opioid antagonist.
9. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said opioid agonist is selected from the group consisting of codeine, dihydrocodeine, hydrocodone, hydromorphone, levorphanol, meperidine, buprenorphine, fentanyl, fentanyl derivatives, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, methadone, morphine, and propoxyphene and pharmaceutically acceptable salts thereof.
10. The abuse resistant oral pharmaceutical dosage form of Claim 9 wherein said opioid agonist is selected from the group consisting of oxycodone, oxymorphone, and morphine.
11. The abuse resistant oral pharmaceutical dosage form of Claim 10 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone and naltrexone.
12. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said coating includes an additional opioid antagonist.
13. The abuse resistant oral pharmaceutical dosage form of Claim 1 wherein said tablet, when intact, is adapted to release at least about 30% of the total opioid antagonist in the first hour, and not more than about 75% in 12 hours, based on dissolution according to USP
XXIV Apparatus I, basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
14. An abuse resistant oral pharmaceutical dosage form comprising:
a first matrix including a first opioid antagonist;
a second matrix including an opioid agonist; and a third matrix including a second opioid antagonist;
wherein said tablet, when intact, is adapted to release at least about 30% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV
Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
15. The abuse resistant oral pharmaceutical dosage form of claim 14 wherein said first matrix is dispersed in said second matrix.
16. The abuse resistant oral pharmaceutical dosage form of claim 14, wherein said first matrix is coated to prevent release of said first opioid antagonist.
17. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein when said tablet is adapted to release, when crushed, at least about 75% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
18. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein said first and second opioid antagonists are the same.
19. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein said first opioid antagonist is naltrexone and said second opioid antagonist is naloxone.
20. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein said opioid agonist is selected from the group consisting of oxycodone, oxymorphone, and morphine.
21. The abuse resistant oral pharmaceutical dosage form of Claim 20 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone and naltrexone.
22. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein said coating includes an additional opioid antagonist.
23. The abuse resistant oral pharmaceutical dosage form of Claim 14 wherein said tablet, when intact, is adapted to release at least about 30% of the total opioid antagonist in the first hour, and not more than about 75% in 12 hours, based on dissolution according to USP
XXIV Apparatus I, basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
24. An abuse resistant oral pharmaceutical dosage form comprising:
a first matrix including a first opioid antagonist;
a second matrix including an opioid agonist; and a coating including a second opioid antagonist;
wherein said tablet, when intact, is adapted to release at least about 0.3 mg of said second opioid antagonist in the first hour based on dissolution according to USP XX1V
Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
25. The abuse resistant oral pharmaceutical dosage form of Claim 24 wherein when said tablet is adapted to release, when crushed, at least about 75% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
26. The abuse resistant oral pharmaceutical dosage form of Claim 24 wherein said first and second opioid antagonists are the same.
27. The abuse resistant oral pharmaceutical dosage form of Claim 24 wherein said opioid agonist is selected from the group consisting of oxycodone, oxymorphone, and morphine.
28. The abuse resistant oral pharmaceutical dosage form of Claim 24 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone and naltrexone.
29. The abuse resistant oral pharmaceutical dosage form of Claim 24 wherein said coating includes an additional opioid antagonist.
30. The abuse resistant oral pharmaceutical dosage form of Claim 26 wherein said coating includes an additional opioid antagonist.
31. An abuse resistant oral pharmaceutical dosage form comprising:
a first matrix including a first opioid antagonist; and a second matrix including an opioid agonist; and a third matrix including a second opioid antagonist;
wherein said tablet, when intact, is adapted to release at least about 0.3 mg of said second opioid antagonist in the first hour based on dissolution according to USP HIV
Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
32. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein when said tablet is adapted to release, when crushed, at least about 75% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
33. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein said first and second opioid antagonists are the same.
34. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein said opioid agonist is selected from the group consisting of codeine, dihydrocodeine, hydrocodone, hydromorphone, levorphanol, meperidine, buprenorphine, fentanyl, fentanyl derivatives, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, methadone, morphine, and propoxyphene.
35. The abuse resistant oral pharmaceutical dosage form of Claim 34 wherein said opioid agonist is selected from the group consisting of oxycodone, oxymorphone, and morphine.
36. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone, naltrexone, nalorphine, diprenorphine, levallorphan, pentazocine, metazocine, cyclazocine, etazocine, N -cyclopropylmethyl - 7,8 - dihydro - 14 - hydroxynormorphinone, and 21 -cyclopropyl z, - (1 hydroxy - 1 - methylethyl) - 6,14 - endo - ethano -tetrahydrooripavine (or diphenorphine).
37. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone and naltrexone.
38. The abuse resistant oral pharmaceutical dosage form of Claim 31 wherein said coating includes an additional opioid antagonist.
39. The abuse resistant oral pharmaceutical dosage form of Claim 33 wherein said coating includes an additional opioid antagonist.
40. An abuse resistant oral pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist, wherein said tablet, when intact, is adapted to release at least about 30% of the total opioid antagonist in the first hour, and not more than about 75% in 12 hours, based on dissolution according to USP XXIV Apparatus I, basket method at 100 rpm using 0.1 N
HCl as dissolution medium at 37.5°C.
41. The abuse resistant oral pharmaceutical dosage form of Claim 40 wherein when said tablet, when intact, is adapted to release at least about 40% of the total opioid antagonist in the first hour, and not more than 65% in I2 hours.
42. The abuse resistant oral pharmaceutical dosage form of Claim 40 wherein when said tablet is adapted to release, when crushed, at least about 75% of the total opioid antagonist in the first hour based on dissolution according to USP XXIV Apparatus I, Basket method at 100 rpm using 0.1 N HCl as dissolution medium at 37.5°C.
43. The abuse resistant oral pharmaceutical dosage form of Claim 40 wherein said tablet includes two opioid antagonists.
44. The abuse resistant oral pharmaceutical dosage form of Claim 40 wherein said opioid agonist is selected from the group consisting of oxycodone, oxymorphone, and morphine.
45. The abuse resistant oral pharmaceutical dosage form of Claim 43 wherein at least one of said opioid antagonists is selected from the group consisting of naloxone and naltrexone.
46. An abuse resistant oral pharmaceutical dosage form comprising a first matrix including a first opioid antagonist, a second matrix including an opioid agonist, and a coating including a second opioid antagonist.
47. The abuse resistant oral pharmaceutical dosage form of claim 46 wherein said first and second opioid antagonists are the same.
48. The abuse resistant oral pharmaceutical dosage form of claim 46 wherein said coating includes two different opioid antagonists.
49. The abuse resistant oral pharmaceutical dosage form of claim 47 wherein said coating includes two different opioid antagonists.
50. The abuse resistant oral pharmaceutical dosage form of claim 48 wherein said antagonists are selected from the group consisting of naloxone, naltrexone, naloiphine, diprenorphine, levallorphan, pentazocine, metazocine, cyclazocine, etazocine, N -cyclopropylmethyl - 7,8 - dihydro - 14 - hydroxynormorphinone, and 21 -cyclopropyl z, - (1 -hydroxy - 1 - methylethyl) - 6,14 - endo - ethano -tetrahydrooripavine (or diphenorphine).
51. The abuse resistant oral pharmaceutical dosage form of claim 50 wherein said antagonists are naloxone and naltrexone.
52. An abuse resistant oral pharmaceutical dosage form comprising a first matrix including a first opioid antagonist, a second matrix including an opioid agonist, and a third matrix including a second opioid antagonist.
53. The abuse resistant oral pharmaceutical dosage form of claim 52 wherein said first and second opioid antagonists are the same.
54. The abuse resistant oral pharmaceutical dosage form of claim 52 wherein said coating includes two different opioid antagonists.
55. The abuse resistant oral pharmaceutical dosage form of claim 53 wherein said coating includes two different opioid antagonists.
56. The abuse resistant oral pharmaceutical dosage form of claim 54 wherein said antagonists are selected from the group consisting of naloxone, naltrexone, nalorphine, diprenorphine, levallorphan, pentazocine, metazocine, cyclazocine, etazocine, N -cyclopropylimethyl - 7,8 - dihydro - 14 - hydroxynormorphinone, and 21 -cyclopropyl z, - (1 -hydroxy - 1 - methylethyl) - 6,14 - endo - ethano -tetrahydrooripavine (or diphenorphine).
57. The abuse resistant oral pharmaceutical dosage form of claim 56 wherein said antagonists are naloxone and naltrexone.
CA2446738A 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form Expired - Lifetime CA2446738C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2778114A CA2778114A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29043801P 2001-05-11 2001-05-11
US60/290,438 2001-05-11
PCT/US2002/015021 WO2002092059A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2778114A Division CA2778114A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Publications (2)

Publication Number Publication Date
CA2446738A1 true CA2446738A1 (en) 2002-11-21
CA2446738C CA2446738C (en) 2012-05-29

Family

ID=23115998

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2778114A Abandoned CA2778114A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form
CA2446738A Expired - Lifetime CA2446738C (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2778114A Abandoned CA2778114A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Country Status (10)

Country Link
US (6) US20030004177A1 (en)
EP (1) EP1389092B1 (en)
JP (3) JP2005515960A (en)
CN (2) CN101439024A (en)
AT (1) ATE345112T1 (en)
AU (1) AU2002303718B2 (en)
CA (2) CA2778114A1 (en)
DE (1) DE60216078T2 (en)
ES (1) ES2275868T3 (en)
WO (1) WO2002092059A1 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2003522144A (en) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
CN1525851A (en) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
WO2002094172A2 (en) * 2001-05-22 2002-11-28 Euro-Celtique Compartmentalized dosage form
EP2311460A1 (en) 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
EP1404331B1 (en) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Sustained release formulations of oxymorphone
SI1416842T1 (en) * 2001-07-18 2009-06-30 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
ES2326794T3 (en) 2001-08-06 2009-10-20 Euro-Celtique S.A. FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS.
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
CA2464528A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
ES2546010T3 (en) 2002-04-05 2015-09-17 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
PT1551372T (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and metohds
JP5189242B2 (en) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド Abuse-resistant pharmaceutical composition
DE10250088A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US9579286B2 (en) * 2003-04-21 2017-02-28 Purdue Pharma L.P. Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP2316440A1 (en) 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1691892B1 (en) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
BRPI0508769A (en) * 2004-03-30 2007-08-28 Euro Celtique Sa tamper-resistant dosage form comprising an adsorbent and an adverse agent
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
HUE037643T2 (en) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Abuse-deterrent drug formulations
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070020339A1 (en) * 2005-07-20 2007-01-25 Pharmorx Inc. Compositions and methods for controlling abuse of medications
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
BRPI0709606B8 (en) 2006-03-16 2021-05-25 Tris Pharma Inc orally administrable liquid suspension with modified release characteristics
EP2007389A2 (en) * 2006-04-14 2008-12-31 Shire LLC Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
PL2526932T3 (en) * 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP1897544A1 (en) * 2006-09-05 2008-03-12 Holger Lars Hermann Opioid agonist and antagonist combinations
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2010506833A (en) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド Pharmaceutical composition
CA2677691C (en) * 2007-02-12 2012-07-31 David Bar-Or Reducing side effects of tramadol
WO2008100926A1 (en) * 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
AU2014250614B2 (en) * 2007-09-04 2016-11-10 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2009032270A2 (en) * 2007-09-04 2009-03-12 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5651818B2 (en) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド Controlled release formulation to prevent misuse
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
ES2635733T3 (en) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Use of opioid antagonists to treat urinary retention
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
PL2379111T3 (en) * 2008-12-12 2013-08-30 Paladin Labs Inc Narcotic drug formulations with decreased abuse potential
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX347753B (en) * 2010-02-24 2017-05-10 Cima Labs Inc Abuse-resistant formulations.
CH705273B1 (en) * 2010-05-10 2016-06-15 Euro Celtique Sa Pharmaceutical composition - comprising hydromorphone and naloxone.
MX2012012991A (en) 2010-05-11 2012-11-30 Cima Labs Inc Alcoholres i stant metoprolol - containing extended - release oral dosage forms.
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
ES2643291T3 (en) 2010-12-22 2017-11-22 Purdue Pharma L.P. Controlled release dosage forms with inviolable closure coated
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
KR20160031038A (en) 2011-02-02 2016-03-21 알파마 파머슈티컬스 엘엘씨 Pharmaceutical composition comprising opioid agonist and sequestered antagonist
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
DK2736497T3 (en) 2011-07-29 2017-11-13 Gruenenthal Gmbh Shock-resistant tablet that provides an immediate release of a drug.
BR112014003651B1 (en) * 2011-08-18 2022-03-29 Biodelivery Sciences International, Inc Misuse-resistant mucoadhesive devices for the release of buprenorphine
SI2915525T1 (en) 2011-09-19 2022-01-31 Orexo Ab Sublingual abuse-resistant tablets comprising buprenorphine and naloxone
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
KR101840526B1 (en) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 Tamper resistant pharmaceutical formulations
CN105120659A (en) 2013-03-15 2015-12-02 度瑞公司 Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20160031526A (en) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN105916505A (en) 2013-11-13 2016-08-31 欧洲凯尔特公司 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015089530A1 (en) * 2013-12-20 2015-06-25 G.L. PHARMA GmbH Extended-release oral dosage form containing morphine and naloxone
EP3086789A4 (en) * 2013-12-23 2017-08-02 Purdue Pharma L.P. Opioid antagonist formulations
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (en) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxone monopreparation and multi-layer tablet
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2018119033A1 (en) * 2016-12-20 2018-06-28 Cima Labs Inc. Abuse-resistant and abuse-deterrent dosage forms
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1172767A (en) * 1912-12-02 1916-02-22 Levi S Couplin Fly-trap.
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5422943A (en) * 1992-09-30 1995-06-06 At&T Corp. Private branch exchange networks
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
DE19651551C2 (en) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
EP2246058A1 (en) * 1997-09-04 2010-11-03 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
RU2241458C2 (en) * 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
CN1204890C (en) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 Method for preventing abuse of opioid dosage forms
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19901687B4 (en) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioid controlled release analgesics
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2003522144A (en) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
CN1525851A (en) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
ES2326794T3 (en) * 2001-08-06 2009-10-20 Euro-Celtique S.A. FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS.
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1691892B1 (en) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP1898891A2 (en) * 2005-05-13 2008-03-19 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
US20070020339A1 (en) * 2005-07-20 2007-01-25 Pharmorx Inc. Compositions and methods for controlling abuse of medications
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
PL2526932T3 (en) * 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine

Also Published As

Publication number Publication date
ATE345112T1 (en) 2006-12-15
JP2005515960A (en) 2005-06-02
EP1389092A1 (en) 2004-02-18
DE60216078D1 (en) 2006-12-28
CA2778114A1 (en) 2002-11-21
ES2275868T3 (en) 2007-06-16
DE60216078T2 (en) 2007-07-05
WO2002092059A1 (en) 2002-11-21
EP1389092B1 (en) 2006-11-15
US20110020444A1 (en) 2011-01-27
AU2002303718B2 (en) 2008-02-28
US20130209561A1 (en) 2013-08-15
CA2446738C (en) 2012-05-29
JP2013053165A (en) 2013-03-21
US20030004177A1 (en) 2003-01-02
US20120231075A1 (en) 2012-09-13
US20120237603A1 (en) 2012-09-20
JP2009143964A (en) 2009-07-02
US20110135731A1 (en) 2011-06-09
CN101439024A (en) 2009-05-27
CN1592609A (en) 2005-03-09

Similar Documents

Publication Publication Date Title
CA2446738A1 (en) Abuse-resistant opioid dosage form
HUP0102658A2 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
US10588865B2 (en) Tamper resistant oral opioid agonist formulations
RU2000119778A (en) COMBINATIONS AGONIST / OPIOID ANTAGONIST
CA2547334A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
CA2640339C (en) Tamper resistant opioid dosage forms
CA2314896C (en) A method of preventing abuse of opioid dosage forms
JP2006524249A5 (en)
JP2010511683A5 (en)
ZA200400893B (en) Opioid agonist formulations with releasable and sequestered antagonist.
JP2008534564A5 (en)
RU2000119779A (en) METHOD FOR PREVENTING ABUSE OF OPIOID-CONTAINING MEDICINAL FORMS
RU2009101082A (en) PHARMACEUTICAL COMPOSITIONS
AU2002303718A1 (en) Abuse-resistant opioid dosage form
JP2009541320A5 (en)
JP2006522013A5 (en)
JP2006524261A5 (en)
EP2101740A1 (en) New non-abusable pharmaceutical composition comprising opioids
JP2011126895A5 (en)
RU2012124063A (en) MEDICINAL COMBINATION WITH THEOBROMIN AND ITS USE IN TREATMENT
AU2003200858B2 (en) A Method of Preventing Abuse of Opioid Dosage Forms
Tsurumi The action of opiate on the intestine-especially the action of opiate on the diarrhea in mice
AU2011202866B2 (en) Tamper resistant dosage forms

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220510